BRIEF-Pharming Group announces acquisition of all North American commercialisation rights to Ruconest from Valeant

Tue Aug 9, 2016 6:19am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 9 (Reuters) - Pharming Group NV :

* Announces acquisition of all North American commercialisation rights to Ruconest from Valeant

* $125 million deal value, with an upfront fee for Valeant of US$60 million, and self-funding sales milestone payments up to a further US$65 million in total

* Funding through a combination of straight debt and new equity capital of between US$ 80-100 million Source text for Eikon: Further company coverage: (Gdynia Newsroom)